新天藥業(002873.SZ)半年度淨利潤升6.5%至3501.9萬元
格隆匯8月21日丨新天藥業(002873.SZ)發佈2019年半年度報告,實現營業收入3.65億元,同比增長13.92%;歸屬於上市公司股東的淨利潤3501.90萬元,同比增長6.50%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3373.34萬元,同比增長15.41%;基本每股收益0.3028元。
隨着《中華人民共和國中醫藥法》的頒佈和實施,“兩票制”、仿製藥質量和療效一致性評價等政策的持續推進,醫藥行業在結構調整中不斷優化發展的新格局正逐步形成,業內企業之間優勝劣汰的分化趨勢更加明顯。同時省級醫保目錄調整、藥品招標的力度加大,三明模式的全國推行,藥業企業既遇到更多新困難新挑戰,也面臨通過變革與創新攻堅克難實現新突破新發展的重大機遇。公司始終堅持致力於應用現代科技理念與成果,依託貴州省豐富的中藥材資源,研究和開發“説得清、道得明”的現代中藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.